Candel reports Phase 3 win, GAAP profit from warrant revaluation; cash runway into Q1 2027

Snapshot - Candel Therapeutics, Inc. (NASDAQ: CADL)

What's happening inside the company (quick summary)

- Cash-rich for now: management reports cash & cash equivalents of about $100.7 million at June 30, 2025 and expects funding into Q1 2027.

- Clinical progress driving expense but also value: positive phase‑3 topline in CAN‑2409 (localized prostate cancer) and encouraging PDAC, NSCLC and CAN‑3110 data. Company plans a BLA submission for CAN‑2409 in Q4 2026.

- GAAP volatility from non‑cash items: a large swing in the fair value of warrant liability produced a non‑cash income item that turned a six‑month operating loss into a GAAP net income for the period.

Positive aspects on the income statement and position

- Six months ended June 30, 2025: reported net income of $2.583 million (GAAP), driven primarily by a $20.572 million decrease in the fair value of the Series B warrant liability (non‑cash).

- Strong interest income: $1.860 million for the six months (Q2 interest income $926k) reflects higher invested cash balances.

- R&D is scaling to support multiple development programs - clinical development spend rose materially (clinical development Q2 2025 $3.051M vs Q2 2024 $0.921M), which is consistent with active Phase‑3 and supportive trials.

- Financing activity replenished cash during the period: registered direct offering net proceeds ~$15.0M (gross $15.044M) plus ATM proceeds $5.038M during the six months.

Negative aspects on the income statement and key risks

- Operating losses remain: loss from operations for the six months ended June 30, 2025 was $(19.307) million and for Q2 alone $(11.177) million - R&D + G&A continue to consume cash.

- Reported GAAP profitability for the six months is driven by a non‑cash accounting gain (warrant liability mark‑to‑market). This is not operational cash flow improvement - operating cash used in the six months was $(17.507) million.

- Accumulated deficit: $189.6 million as of June 30, 2025 - company remains historically loss‑making and dependent on financing.

- Debt and near‑term maturities: term loan carrying current portion $6.704M (loan matures Jan 1, 2026); other long‑term debt includes a Periphagen note carrying value ~$0.9M due Nov 2027.

- Warrant liability creates earnings volatility: warrant liability fell from $21.718M (Dec 31, 2024) to $1.146M (June 30, 2025) - that swing drove the GAAP performance but is non‑recurring and market‑driven.

Key facts & statistics (as reported)

- Cash & cash equivalents (June 30, 2025): ~$100.7 million.

- Total assets: $105,968 thousand (≈ $106.0M); Total liabilities: $15,758 thousand (≈ $15.8M).

- Current liabilities included a warrant liability of $1,146 thousand at June 30, 2025 (was $21,718 thousand at 12/31/2024).

- Shares outstanding (reported Aug 5, 2025): 54,895,099 shares.

- Three months ended June 30, 2025 (comparative Q2 2024): R&D $6,991k (vs $4,979k); G&A $4,186k (vs $3,592k); Total operating expenses $11,177k (vs $8,571k); Loss from operations $(11,177)k (vs $(8,571)k).

- Six months ended June 30, 2025 vs 2024: Total operating expenses $19,307k (vs $16,473k); Interest income $1,860k (vs $560k); Change in fair value of warrant liability +$20,572k (vs -$13,332k); Net income (loss) $2,583k (vs $(30,458)k).

- Cash flow: net cash used in operating activities for six months ended June 30, 2025: $(17,507)k; net cash provided by financing activities: $15,574k (includes Registered Direct ~$15.0M and ATM proceeds ~$5.0M less $5.0M principal payment on term loan).

- Term loan: scheduled principal remaining $5,000k in 2025 and $833k in 2026; final payment fee approx $900k; weighted average effective interest rate 11.79% as of 6/30/2025.

Clinical and corporate highlights that matter for finances

- CAN‑2409: pivotal Phase 3 met primary endpoint for disease‑free survival (DFS) - p=0.0155; HR 0.70 (95% CI 0.52-0.94); median DFS not reached (CAN‑2409) vs 86.1 months (placebo).

- Secondary / supportive signals reported for CAN‑2409: prostate‑cancer specific DFS p=0.0046 (HR 0.62); PSA nadir <0.2 ng/ml 67.1% vs 58.6% (p=0.0164); pathological complete response in 2‑year biopsies 80.4% vs 63.6% (p=0.0015).

- Regulatory designations: FDA RMAT for CAN‑2409 in newly diagnosed localized prostate cancer (intermediate‑to‑high risk); multiple Fast Track and orphan designations on other programs.

- Management expects a BLA submission for CAN‑2409 in Q4 2026 (per MD&A).

Bottom line / what to watch next

- Cash runway is a key near‑term metric: the company says funds into Q1 2027 - monitor cash burn, operating cash flow trends and any further financings.

- Earnings are volatile and GAAP positive in the first half of 2025 only because of a non‑cash revaluation of warrants - don't mistake that for operational profitability.

- Clinical readouts and regulatory milestones (BLA timing, confirmatory OS data in other indications, FDA interactions) will determine medium‑term value creation; their costs will keep R&D spend elevated.

- Debt maturities (term loan due Jan 2026) and capital‑raising execution are near‑term balance‑sheet risks to watch.

Concise verdict: Candel (NASDAQ: CADL) is cash‑funded for now and reporting headline clinical progress that underpins future value, but GAAP profitability in H1 2025 is an accounting artifact (warrant re‑measurement). The company remains R&D‑heavy, dependent on future fundraisings, and exposed to near‑term debt maturities - monitor cash burn, financing actions, and regulatory milestones (BLA timing and reviews).